Invex Therapeutics Ltd.

As of June 30, 2025, Invex Therapeutics Ltd. carries a market capitalization of 6.69M, placing it among publicly traded companies globally. Its enterprise value stands at 1.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Invex Therapeutics Ltd.'s next confirmed earnings release is scheduled for February 18, 2027.

As of June 30, 2025, Invex Therapeutics Ltd. has 75.15M shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Invex Therapeutics Ltd. maintains a current ratio of 24.79, meaning it holds 24.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Invex Therapeutics Ltd. posted a negative return on equity (ROE) of -8.72, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.23, reflecting losses generated across the asset base.

As of the close on October 19, 2026, Invex Therapeutics Ltd.'s stock has declined approximately 25.00% over the past 52 weeks. The 50-day moving average sits at 0.11, while the 200-day moving average is 0.11.

These figures cover the twelve months ended June 30, 2025. EBITDA reached -951,222.00, while operating income came in at -951,222.00.

These figures are as of June 30, 2025. Total book value stands at 5.25M, with working capital of 5.25M providing operational flexibility.